Genomma Lab Internacional, S.A.B. de C.V.
GNMLF
$1.43
$0.169913.48%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.95% | 10.26% | 11.11% | 13.92% | 10.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.95% | 10.26% | 11.11% | 13.92% | 10.90% |
| Cost of Revenue | 1.36% | 4.41% | 8.74% | 17.97% | 15.47% |
| Gross Profit | 13.95% | 14.13% | 12.66% | 11.43% | 8.09% |
| SG&A Expenses | 11.69% | 13.31% | 12.17% | 9.18% | 6.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 290.52% | 338.84% | -958.29% | 97.37% | 62.66% |
| Total Operating Expenses | 7.59% | 9.13% | 10.40% | 14.26% | 11.38% |
| Operating Income | 14.63% | 14.98% | 14.07% | 12.53% | 8.97% |
| Income Before Tax | 1.27% | -11.43% | -13.58% | 7.15% | 6.84% |
| Income Tax Expenses | -0.87% | -12.25% | -16.82% | -5.19% | -1.86% |
| Earnings from Continuing Operations | 2.43% | -10.95% | -11.55% | 15.11% | 12.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 2.43% | -10.95% | -11.55% | 15.11% | 12.29% |
| EBIT | 14.63% | 14.98% | 14.07% | 12.53% | 8.97% |
| EBITDA | 14.47% | 15.18% | 14.02% | 13.07% | 9.99% |
| EPS Basic | 6.01% | -8.53% | -8.92% | 18.28% | 14.18% |
| Normalized Basic EPS | 4.88% | -8.85% | -10.78% | 9.37% | 7.89% |
| EPS Diluted | 6.01% | -8.53% | -8.92% | 18.28% | 14.18% |
| Normalized Diluted EPS | 4.88% | -8.85% | -10.78% | 9.37% | 7.89% |
| Average Basic Shares Outstanding | -3.56% | -3.25% | -3.64% | -2.55% | -1.59% |
| Average Diluted Shares Outstanding | -3.56% | -3.25% | -3.64% | -2.55% | -1.59% |
| Dividend Per Share | -15.85% | 52.51% | 128.35% | 185.33% | 122.83% |
| Payout Ratio | 0.46% | 0.28% | -0.04% | -0.05% | -0.29% |
